For Research Purposes Only — This compound is not FDA approved.

Catalog
GLOW
Dermal Research

GLOW

A multi-peptide research blend studied for dermal and tissue-repair signaling in research models. Premium Research Peptide.

Amount
Quantity
1
Bundle & Save
COA
Only 42 left in stock 18 people viewing now
Est. delivery in 2–5 business days
Free shipment protection
Overnight shipping available

Certificate of Analysis

Third Party Tested Freedom Diagnostics
99.67%
Purity · HPLC-UV
Latest BatchLC-MS IdentityUS Tested
Passed QC panel
Lot GL70-001Tested Aug 11, 2026
Purity (HPLC-UV)99.67%
Net Peptide Content80.01mg
Identity (LC-MS)GHK-Cu / TB-500 / BPC-157
Endotoxin (USP <85>)Pass · ≤0.05 EU/mL
Freedom Diagnostics · Independent third-party lab View full COA

Compound Information

Technical specifications
Molecular Profile

What is GLOW?

TypePeptide blend
CAS NumberBlend — see composition
Molecular WeightBlend — see composition
Amino AcidsBlend — see composition
CompositionGHK-Cu 50mg · BPC-157 10mg · TB-500 10mg
PubChem Database GLOW Blend Research Guide
Storage Requirements

Stability Information

Avoid freeze/thaw cyclesProtect from lightKeep refrigerated
Lyophilized (powder)
−20°C · 24+ months
Reconstituted
2–8°C · ~30 days

Research Background

For laboratory research use only

What the GLOW blend contains

GLOW is a three-component blend lyophilised in a single vial: GHK-Cu, BPC-157 and TB-500, in the amounts shown on the specification card above. The three are chemically unrelated. GHK-Cu is the copper(II) complex of a tripeptide, glycyl-histidyl-lysine. BPC-157 is a synthetic 15-amino-acid peptide. TB-500 is the trade name for thymosin beta-4, a 43-amino-acid actin-binding peptide. They span more than a tenfold range in molecular weight, and one of them carries a metal ion, which is why the blend is blue.

The name is a trade designation used across the research-supply market for this combination, not a term from the scientific literature. A search of published papers for the three-way mixture will find very little.

What the preclinical literature has examined

  • GHK-Cu. Fibroblast-culture studies of collagen and glycosaminoglycan synthesis, matrix metalloproteinases, and gene-expression profiling.
  • BPC-157. Rodent models of tendon, muscle and gastrointestinal injury, and cell studies of growth-factor receptor expression.
  • Thymosin beta-4. Actin sequestration, cell-migration and angiogenesis assays, and animal models of dermal and other tissue injury.
  • The combination. There is no substantial body of published work on the three together. Any hypothesis about how they interact is extrapolated from three separate single-compound literatures, and an experiment using the blend cannot attribute an observation to one component without the matching single-compound controls.

None of the three is an approved drug. This material is supplied for in vitro and laboratory research only and is not for human, veterinary or cosmetic use. The GLOW blend research guide covers the blend, and the GHK-Cu, BPC-157 and BPC-157 / TB-500 guides cover the components.

How a three-component blend is characterised

Every analytical question doubles or triples in a blend. An HPLC trace should show a main peak for each component, and they elute far apart: the tripeptide complex early, the two larger peptides later. LC-MS identity has to find all three molecular masses, and confirming two says nothing about the third. Net peptide content is the measured peptide mass in the vial, and the endotoxin result is relevant to any cell-based work. These are the lines to look for on the Certificate of Analysis above. HPLC vs mass spectrometry explains why both methods are needed, and how to read a Certificate of Analysis goes through each line.

Handling in the laboratory

A blend inherits the constraints of all its parts. From GHK-Cu: chelators such as EDTA, strongly acidic buffers and reducing agents will strip or alter the copper, so check buffer recipes first. From thymosin beta-4: its methionine residue oxidises readily, so limit exposure to air and light. Putting a copper complex and an oxidation-sensitive peptide in one solution is a further reason to keep solutions cold, protected from light and short-lived. Keep the lyophilised powder frozen and dry, reconstitute by gentle swirling, and divide the stock into single-use aliquots on the day it is made. See peptide storage and stability and how to reconstitute a research peptide.

Common questions

What is in the GLOW blend?

Three components lyophilised together: GHK-Cu, BPC-157 and TB-500 (thymosin beta-4). The amount of each is listed in the composition line of the specification card on this page.

Why is the GLOW blend blue?

The colour comes from GHK-Cu, which is a copper(II) complex. A blue powder and solution are expected. Loss of colour suggests the copper has been removed or altered, for example by a chelator such as EDTA.

Is there published research on the three peptides together?

Very little. Each component has its own preclinical literature, but the three-way combination has not been studied to any comparable extent. Experiments with the blend need single-compound controls to attribute an effect to one component.

Is the GLOW blend approved for human or cosmetic use?

No. None of the three components is an approved drug. This material is sold for in vitro and laboratory research only and is not for human, veterinary or cosmetic use.

How is a three-peptide blend verified?

HPLC should show a main peak for each component and LC-MS should find all three molecular masses. Net peptide content gives the measured peptide mass in the vial. These results are reported on the Certificate of Analysis for the lot.

Frequently Researched Together

Important Research Notice

Not for human consumption. This product is sold exclusively for research and educational purposes. It is not intended to diagnose, treat, cure, or prevent any disease.

By purchasing, you confirm that you are a qualified researcher and will use these products in accordance with all applicable laws and regulations.